Zylox-Tonbridge Medical Technology Co., Ltd. (“ZYLOXTB”) has reported the repurchase of 54,000 H shares on 25 September 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The shares were acquired on-market at prices ranging between HKD 20.98 and HKD 21.60, for a total consideration of HKD 1.16 million. The weighted-average price disclosed for reporting purposes was RMB 21.4281 per share.

Capital structure impact: • Issued shares (excluding treasury) fell from 322.44 million to 322.38 million, a reduction of 0.016%. • Treasury stock increased from 13.91 million to 13.97 million shares. • Total issued shares remained unchanged at 336.35 million.

Buyback mandate status: • The current mandate, approved on 13 May 2026, authorises repurchases of up to 32.72 million shares. • Cumulative repurchases under this mandate now stand at 5.07 million shares, equivalent to 1.51% of the issued share count on the mandate date.

In line with Hong Kong listing rules, ZYLOXTB is subject to a moratorium on new share issues or sales of treasury shares until 25 October 2026. Management has confirmed that the transaction complied with all relevant regulatory and corporate requirements.